
E.2 Transcatheter valve implantation


E.2.1 SAPT versus DAPT

Figure 13: All-cause mortality at ≤12 months for SAPT versus DAPT in transcatheter valve implantation



Note: Odds ratio used because this summary statistic was reported for the two studies included in the IPD MA.

Figure 14: Major bleeding at ≤12 months for SAPT versus DAPT in transcatheter valve implantation



Note: Odds ratio used because this summary statistic was reported for the two studies included in the IPD MA.

Figure 15: Minor bleeding at ≤12 months for SAPT versus DAPT in transcatheter valve implantation



Figure 16: Arterial thromboembolic events at ≤12 months for SAPT versus DAPT in transcatheter valve implantation

				Odds Ratio		Odds Ratio	
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Fixed, 95% CI		IV, Fixed, 95% CI	
Rodes-Cabau 2017 (ARTE)	-1.2997	0.8134		0.27 [0.06, 1.34]		+++	
Stabile 2014 (SAT-TAVI)	0.708	1.2362		2.03 [0.18, 22.89]		 	
Ussia 2011	0.7467	1.2559		2.11 [0.18, 24.73]		 	
					0.01	0.1 1 10 100	4
					0.01	Favours SAPT Favours DAPT	<u> </u>

Note: Reported as a range of odds ratios due to heterogeneity between studies with a large difference in point estimates without sufficient study number to form valid subgroups. Odds ratio used because this summary statistic was reported for the two studies included in the IPD MA.

Figure 17: Stroke (arterial thromboembolic events) at 12 months for SAPT versus DAPT in transcatheter valve implantation




Figure 18: Myocardial infarction (arterial thromboembolic events) at 12 months for SAPT versus DAPT in transcatheter valve implantation




Figure 19: Symptomatic clinical aortic valve thrombosis (thrombus on imaging) at 12 months for SAPT versus DAPT in transcatheter valve implantation





Figure 20: Mean aortic valve gradient (valve degeneration) at 6 months for SAPT versus DAPT in transcatheter valve implantation (better indicated by lower values)



MIDs used to assess imprecision were calculated by multiplying the median baseline SD across study arms (5.2) by 0.5 and were ± 2.60 .

E.2.2 DOAC (+ aspirin for 3 months) versus aspirin (+ clopidogrel for 3 months)

Figure 21: All-cause mortality at median treatment duration of 428 days



Figure 22: Major bleeding (VARC-2 life-threatening, disabling or major bleeding) at median treatment duration of 428 days




Figure 23: Major bleeding (BARC type 2, 3 or 5 bleeding) at median treatment duration of 428 days



Figure 24: Major bleeding (ISTH major bleeding) at median treatment duration of 428 days



Figure 25: Major/minor bleeding (TIMI major or minor bleeding) at median treatment duration of 428 days

	DOAC (+ 3 mont	h aspirin)	Aspirin (+3 mo	nth clopid)	Risk Ratio	Risk Ratio								
Study or Subgroup	Events	Total	Events	Total	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI							
Dangas 2020 (GALILEO)	42	826	24	818	1.73 [1.06, 2.83]									
						-								
						0.1	0.2	0.5	1	2	5	10		
							Favours DOAC + 3 mth SAPT Favours SAPT (3 mth DAPT)							

Figure 26: Stroke (arterial thromboembolic events) at median treatment duration of 428 days

	DOAC (+ 3 month	h aspirin)	Aspirin (+3 mo	nth clopid)	Risk Ratio	Risk Ratio								
Study or Subgroup	Events	Total	Events	Total	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI							
Dangas 2020 (GALILEO)	30	826	25	818	1.19 [0.71, 2.00]			-						
						\vdash		-	-+			-		
						0.1	0.2	0.5	1	2	5	10		
							Favours DO	AC + 3 mth S	APT Fav	ours SAPT (3	mth DAPT)			

Figure 27: Myocardial infarction (arterial thromboembolic events) at median treatment duration of 428 days



Figure 28: Pulmonary embolism (arterial thromboembolic events) at median treatment duration of 428 days

	DOAC (+ 3 mont	h aspirin)	Aspirin (+3 mo	onth clopid)	Peto Odds Ratio	Peto Odds Ratio								
Study or Subgroup	Events	Total	Events	Total	Peto, Fixed, 95% CI		Peto, Fixed, 95% CI							
Dangas 2020 (GALILEO)	3	826	2	818	1.48 [0.26, 8.55]		_			+		_		
						-						-		
						0.1	0.2	0.5	1	2	5	10		
							Favours DO	Favours DOAC + 3 mth SAPT Favours SAPT (3 mth DAPT)						

Figure 29: Systemic embolism (arterial thromboembolic events) at median treatment duration of 428 days




Figure 30: Premature study drug discontinuation due to adverse events (thromboembolic, bleeding or other adverse events) at median treatment duration of 428 days



Figure 31: Symptomatic valve thrombosis (thrombus on imaging) at median treatment duration of 428 days



E.2.3 Anticoagulant (VKA or DOAC) + SAPT (clopidogrel) versus anticoagulant (VKA or DOAC) alone

Figure 32: All-cause mortality at 12 months




Figure 33: Major bleeding (VARC-2 life-threatening, disabling or major bleeding) at 12 months



Figure 34: Minor bleeding (VARC-2 minor bleeding) at 12 months

	Anticoag + clop	idogrel	Anticoag	alone	Risk Ratio	Risk Ratio								
Study or Subgroup	Events	Total	Events	Total	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI								
Nijenhuis 2020 (POPular TAVI cohort B)	28	156	20	157	1.41 [0.83, 2.39]				+	+				
						\vdash	-+-		-		-	$\overline{}$		
						0.1	0.2	0.5	1	2	5	10		
							Favours anticoag + clopid			avours antico	ag alone			

Figure 35: Stroke (arterial thromboembolic events) at 12 months



Figure 36: Myocardial infarction (arterial thromboembolic events) at 12 months





Figure 37: Mean aortic valve gradient (valve degeneration – transvalvular gradient) at 6 months (better indicated by lower values)



MIDs used to assess imprecision were calculated by multiplying the median baseline SD across study arms (5.1) by 0.5 and were $\pm\ 2.55$.